Tim Robinson
@drtimrobinson.bsky.social
Consultant and senior lecturer in medical oncology, University of Bristol. Breast cancer, clinical trials and harm v benefit. Rides a bike sometimes
Reposted by Tim Robinson
The hallmarks of cancer immune evasion
The hallmarks of cancer immune evasion
Cancer cells often evade the host immune system, challenging the effectiveness of
immunotherapy. In this comprehensive review, Galassi et al. summarize key mechanisms
of immune evasion within the “thr...
www.cell.com
November 25, 2024 at 3:45 AM
The hallmarks of cancer immune evasion
Reposted by Tim Robinson
We have an open #PhD #studentship as part of our "Black Leaders in Cancer" programme at @crukconvergence.bsky.social & @icrlondon.bsky.social. About computational modelling of T-cell evolution in cancer. www.findaphd.com/phds/project... I'm looking forward to meeting prospective students #CRUKfunded
www.findaphd.com
November 28, 2024 at 9:40 AM
We have an open #PhD #studentship as part of our "Black Leaders in Cancer" programme at @crukconvergence.bsky.social & @icrlondon.bsky.social. About computational modelling of T-cell evolution in cancer. www.findaphd.com/phds/project... I'm looking forward to meeting prospective students #CRUKfunded
The SONIA trial shows the utility of well-designed academic trials. But funding such studies is getting harder and harder. We need to work with industry to design smarter trials that don’t need further costly and lengthy trials to fill gaps www.nature.com/articles/d41... @oncoalert.bsky.social #bcsm
Toxicity and costs of cancer treatment reduced by deferring CDK4/6 inhibitor use
No difference in survival outcomes between use of CDK4/6 inhibitors as first- or second-line treatment in metastatic breast cancer.
www.nature.com
November 28, 2024 at 8:52 AM
The SONIA trial shows the utility of well-designed academic trials. But funding such studies is getting harder and harder. We need to work with industry to design smarter trials that don’t need further costly and lengthy trials to fill gaps www.nature.com/articles/d41... @oncoalert.bsky.social #bcsm
This is potentially very interesting data but follow up is short at this point and would want to see an EFS/OS outcome. Does provide early signal and could be useful for those where steroids are contraindicated or problematic
Out in @TheLancetOncol
De-escalated neoadjuvant CT with trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer
PCR rate 66.3% vs. 57.6% in the nab-paclitaxel group vs. in the docetaxel + carbo group
@oncoalert.bsky.social
www.thelancet.com/journals/lan...
De-escalated neoadjuvant CT with trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer
PCR rate 66.3% vs. 57.6% in the nab-paclitaxel group vs. in the docetaxel + carbo group
@oncoalert.bsky.social
www.thelancet.com/journals/lan...
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006)...
These findings might suggest a potential advantage of nab-paclitaxel combined with
trastuzumab and pertuzumab compared with the standard regimen in neoadjuvant therapy
for patients with HER2-positive ...
www.thelancet.com
November 28, 2024 at 8:34 AM
This is potentially very interesting data but follow up is short at this point and would want to see an EFS/OS outcome. Does provide early signal and could be useful for those where steroids are contraindicated or problematic
Reposted by Tim Robinson
⏰ Final call!
🧑🔬 Last week to apply for this fantastic opportunity to work with the exceptional @giampazolias.bsky.social at @cruk-mi.bsky.social. #TeamManchester
To apply (deadline 1 Dec 2024):
www.cruk.manchester.ac.uk/recruitment/...
🧑🔬 Last week to apply for this fantastic opportunity to work with the exceptional @giampazolias.bsky.social at @cruk-mi.bsky.social. #TeamManchester
To apply (deadline 1 Dec 2024):
www.cruk.manchester.ac.uk/recruitment/...
November 26, 2024 at 8:56 AM
⏰ Final call!
🧑🔬 Last week to apply for this fantastic opportunity to work with the exceptional @giampazolias.bsky.social at @cruk-mi.bsky.social. #TeamManchester
To apply (deadline 1 Dec 2024):
www.cruk.manchester.ac.uk/recruitment/...
🧑🔬 Last week to apply for this fantastic opportunity to work with the exceptional @giampazolias.bsky.social at @cruk-mi.bsky.social. #TeamManchester
To apply (deadline 1 Dec 2024):
www.cruk.manchester.ac.uk/recruitment/...
Nice review! I’m sure we will have combination strategies in the clinic on the next few years but must balance efficacy with cost/side effect profiles
www.nature.com/articles/s41...
Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang
Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang
Next-generation combination approaches for immune checkpoint therapy - Nature Immunology
In this Review, Sharma and colleagues describe the current landscape of combination therapies and discuss requirements for the development of effective combination strategies.
www.nature.com
November 26, 2024 at 7:53 AM
Nice review! I’m sure we will have combination strategies in the clinic on the next few years but must balance efficacy with cost/side effect profiles
Yep quoting to keep the links!
Amazing! Thanks for these - really useful 👍.
November 23, 2024 at 4:40 PM
Yep quoting to keep the links!
Reassuring BUT short follow up at this time point
Study in #JAMAOnc from Scotland/Wales of nearly 50k #breastcancer patients suggests vaginal estrogen use *NOT* associated w increase risk of breast cancer-specific mortality.
More reassuring data 👍
jamanetwork.com/journals/jam...
More reassuring data 👍
jamanetwork.com/journals/jam...
Vaginal Estrogen Therapy Use and Survival in Breast Cancer
This cohort study compares the mortality risk associated with vaginal estrogen therapy vs no hormone replacement therapy in 2 cohorts of patients with breast cancer in Scotland and Wales.
jamanetwork.com
November 23, 2024 at 4:31 PM
Reassuring BUT short follow up at this time point
Interesting results, be nice to see these replicated in other eTNBC IO trials. Also to explore links with irAEs
Correlative analysis of GeparNuevo #TNBC neoadj clinical trial by Denkert et al:
➡️Expression analyses of tumor biopsies at 3 time points
➡️Confirm role of immune & prolif signatures
➡️Stromal signature assoc w immunotherapy resistance
@oncoalert.bsky.social #BCSM
www.cell.com/cell-reports...
➡️Expression analyses of tumor biopsies at 3 time points
➡️Confirm role of immune & prolif signatures
➡️Stromal signature assoc w immunotherapy resistance
@oncoalert.bsky.social #BCSM
www.cell.com/cell-reports...
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer
Denkert et al. evaluate the longitudinal changes in tumor tissue of triple-negative
breast cancer in a clinical trial cohort treated with neoadjuvant immunotherapy plus
chemotherapy. The role of diffe...
www.cell.com
November 21, 2024 at 3:10 PM
Interesting results, be nice to see these replicated in other eTNBC IO trials. Also to explore links with irAEs
Anecdotally, seeing an awful lot of younger patients with TNBC coming through MDT. Is anyone else seeing this?
November 21, 2024 at 9:38 AM
Anecdotally, seeing an awful lot of younger patients with TNBC coming through MDT. Is anyone else seeing this?
I’m excited to see data at #SABCS but I’m also mindful that we are adding more and more to treatments and feel like we’re reaching the point that we need to start trying smarter patient selection to prevent harm @oncoalert.bsky.social #oncsky
November 20, 2024 at 1:47 PM
I’m excited to see data at #SABCS but I’m also mindful that we are adding more and more to treatments and feel like we’re reaching the point that we need to start trying smarter patient selection to prevent harm @oncoalert.bsky.social #oncsky
We really need some better biomarkers for immunotherapy toxicity…. Im worried we’re storing up psome big issues down the line
November 18, 2024 at 5:57 PM
We really need some better biomarkers for immunotherapy toxicity…. Im worried we’re storing up psome big issues down the line
Well this seems rather pleasant compared to… you know the other place
November 11, 2024 at 4:17 PM
Well this seems rather pleasant compared to… you know the other place